Pharma Focus Europe

Dignify Therapeutics and Aayam Therapeutics Announce Licensing Agreement for a Novel on-demand Bowel Management Medication

Thursday, September 14, 2023

Dignify Therapeutics (Dignify) has recently announced a licensing agreement with Aayam Therapeutics (Aayam) aimed at developing compound ATX-003 and related proprietary molecules to address on-demand defecation. Dignify is a pharmaceutical and medical device development company focused on improving bowel and bladder control for elderly and neurologically impaired individuals.

Company President Dr. Ed Burgard highlighted the significance of this agreement, stating, "This collaboration enhances Dignify's expanding therapeutic pipeline for bowel and bladder disorders. ATX-003 is a de-risked therapeutic option that not only extends Dignify's patent protection but also provides therapeutic relief for individuals dealing with constipation and functional bowel disorders."

Dr. Sundeep Dugar, President of Aayam, emphasized the severity of constipation and functional bowel disorders and the lack of effective therapies, stating, "We are excited to partner with Dignify to advance a safe and efficient treatment for this critical and unmet medical need."

magazine-slider-img
Thermo Fisher Scientific - mRNA ServicesWorld Orphan Drug Congress 2024World Vaccine Congress Europe 2024Advanced Therapies USA 2024
cytiva